You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
南模生物(688265.SH)業績快報:2021年度淨利潤升33.81%至5961.82萬元
格隆匯 02-25 15:58

格隆匯2月25日丨南模生物(688265.SH)披露2021年度業績快報,報吿期內,公司實現營業收入約為2.74億元,同比增長39.89%;實現歸屬於母公司所有者的淨利潤約為5961.82萬元,同比增長33.81%;實現歸屬於母公司所有者的扣除非經常性損益的淨利潤約為5215.71萬元,同比增長59.38%。

隨着國內在生命科學基礎研究投入的不斷加大,以及精準醫療產業的迅速發展,基因修飾模式生物作為重要的實驗工具,為基因功能研究、新靶點發現及新藥藥效評價等提供相應的動物模型和技術服務,已廣泛應用於生命科學領域、醫藥研發和CRO服務領域,市場空間廣闊。報吿期內,公司不斷加大市場開拓力度,科研客户和工業客户對公司基因修飾動物模型及相關技術服務的需求持續上漲,訂單量實現較快增長;同時,公司積極擴大生產規模,金山生產基地已投入運行,為公司生產經營提供了設施保障;加之,公司持續加強技術平台和人才隊伍建設,進一步增強模型產品交付和服務提供能力,提升內部運營效率,促進業績持續穩步增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account